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Abstract
Background: MicroRNAs (miRNAs) are one of the most abundant groups of regulatory genes in
multicellular organisms, playing important roles in many fundamental cellular processes. More than
four hundred miRNAs have been identified in humans and the deregulation of miRNA expression
has been also shown in many cancers. Despite the postulated involvement of miRNAs in
tumourigenesis, there are only a few examples where an oncogene or a tumour suppressor has
been identified as a miRNA target.
Results:  Here, we present an in silico analysis of potential miRNA- oncogene interactions.
Moreover, we have tested the validity of two possible interactions of miRNAs with genes related
to cancer. We present evidence for the down-regulation of c-MYC, one of the most potent and
frequently deregulated oncogenes, by let-7 miRNA, via the predicted binding site in the 3'UTR, and
verify the suppression of BCL-2 by miR16.
Conclusion: In this work both bioinformatic and experimental approaches for the prediction and
validation of possible targets for miRNAs have been used. A list of putative targets for different
oncomirs, validation of which would be of special interest, is proposed and two such interactions
have been experimentally validated.
Background
Originally discovered as a rare example of single-stranded
~22-nt RNA regulators of developmental timing in C. ele-
gans, microRNAs are now regarded as playing an impor-
tant regulatory role in gene expression of animals and
plants [1-5]. Even more, it has turned out that miRNAs are
one of the most abundant groups of regulatory genes in
multicellular organisms [6]. These small RNAs negatively
regulate gene expression at the post-transcriptional level
involving duplex formation between the miRNA and the
messenger RNA. It is believed that the level of comple-
mentarity between these two molecules is decisive of the
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type of regulation achieved by the miRNAs. When the
binding is supported by extensive or complete comple-
mentarity to the coding region of the mRNA, the RNAi
pathway is induced, resulting in the cleavage and degrada-
tion of the target transcript. This type of regulation,
involving RNA-induced silencing complex (miRISC) and
miRNA-directed mRNA cleavage, is widely observed in
plants [5,7-9] but has been also reported to occur in mam-
mals [10]. In animals, however, miRNA-mRNA binding is
more variable, it may contain several mismatches, loops
and bulges, and it is found to take place mainly in the
3'UTR of the messenger molecule [11-16]. This imperfect
complementarity leads to another type of gene regulation
which does not include mRNA cleavage but apparently
inhibition of translation [17,18]. In this case the protein
levels are reduced, but the mRNA abundance in the cell
remains unchanged. Besides these two types of regulation,
recent studies have indicated that there is at least an addi-
tional way in which miRNAs can negatively influence
gene expression. By the same incomplete pairing with the
3'UTR, miRNAs are able to destabilize and reduce mRNA
concentration, by accelerating poly (A) tail removal lead-
ing to miRNA-mediated mRNA decay [19,20]. This type of
mechanism is irreversible, like the mRNA cleavage, and
seems to be an important part of the miRNA-regulatory
network. Another significant feature of the microRNA
binding is the crucial pairing of the miRNA 5'end nucle-
otides [21-25]. Brennecke et al. [26] have suggested the
general structural requirements for the functionality of
miRNA sites with the incomplete complementarity.
Since the discovery of miRNAs, their number and the
examples of their possible functions have dramatically
grown. It has been shown that the expression levels of par-
ticular miRNAs differ depending on the developmental
stage, cell type and tissue [27-29]. Altered expression pat-
tern (over- or under-expression) of specific miRNAs has
been also reported in tissues derived from various
tumours [3,30-33]. A very large portion (more than 50%)
of the human miRNAs are located in so-called "fragile
sites", on chromosomes which are frequently deleted,
amplified or rearranged in case of cancer development
[34]. This data together suggest that the aberrant activity
of miRNAs, influencing basic cellular processes such as
growth, proliferation and differentiation of cells, may
contribute to tumourigenesis. The possible functions of
cancer-related microRNAs, termed recently "oncomirs"
[31,35], have been therefore widely investigated
(reviewed in [35-38]). It was found that miR-15a and
miR-16 were deleted or downregulated in lymphocytic
leukaemia [39]; let-7 was downregulated in lung cancers
[40,41]; the miR-17 cluster was amplified in several types
of lymphoma and solid tumours [31,42,43]; miR-21 was
overexpressed in glioblastoma [44,45] and breast cancer
[46]; levels of miR-143 and miR-145 were decreased in
colorectal neoplasia, breast, prostate and cervical cancers
[46,47]; miR155 was upregulated in Burkitt and B-cell
lymphomas [48-50] and also in breast cancer [46].
Although deregulation of expression of many miRNAs has
been already reported in different cancers, the direct inter-
action between the particular miRNA and mRNA of a spe-
cific oncogene has been proved only in a few cases. More
specifically, experimentally has been shown, the suppres-
sion of RAS oncogene by let-7 [40]; the suppression of
BCL-2 by miR-15a and miR-1 [51]; the regulation of tran-
scription factor E2F1 activity by miR-17-5p and miR-20
[52]; the downregulation of the KIT oncogene by miR-221
and miR-222 [53], the inhibition of the expression of
tumour-supressor LATS2 and the influence on p53 path-
way by miR-372 and miR-373 [54], and finally, the down-
regulation of the proto-oncogene BCL6 by miR-127 [55].
In this work, we present both computational and experi-
mental approaches for verification of human miRNA tar-
get sites. Using bioinformatics methods, we have found a
large number of potential target sites for miRNAs in the
group of oncogenes and genes related to cancer. Further,
by an experimental approach, we have tested the validity
of two possible interactions. We present here evidence
that let-7 binds to the 3'UTR of c-MYC  oncogene and
downregulates its expression. Moreover, we have con-
firmed that miR-16 regulates BCL-2, (previously reported
by others [51]), and we have proposed the other putative
targets for different oncomirs, validation of which would
be of special interest.
Results
In silico analysis
The goal of the bioinformatic analysis was to find poten-
tial binding sites for cloned miRNAs in the set of human
oncogenes. In humans, as in other animals, the miRNA
regulation is accomplished by binding the microRNAs
predominantly to the 3' untranslated region (UTR) of the
messenger RNA. [21,56,57]. For this reason the investiga-
tion and scanning for miRNA:mRNA binding sites was
limited to 3'UTR sequences of Homo sapiens.
After the scanning and filtering of the UTRs oncogenes
dataset (149 sequences), positive results for 294 binding
sites in 80 sequences (genes) from this set were obtained.
Table 1 presents an arbitrary selection of known onco-
genes with their predicted miR-regulators as examples of
the analysis. The whole list is placed as supplementary
material (Additional file 1). Most of the oncogenes pre-
sented contain multiple predicted binding sites in their
UTRs, which is in accordance with the current understand-
ing that a gene is usually regulated by more than one
miRNA, or else contains multiple sites of one miRNA for
a combinatorial or more efficient regulation [18,58,59].BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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Table 1: Examples of predicted miRNA/oncogene interactions
gene name 3'UTR position miRNA name secondary structure free energy
BCL-2 1200 hsa-miR-139 ((((((((.(((((((((&)))))))))..))))))))...
..........
-27.5
BCL-2 2382 hsa-miR-370 ((((...((.(((((((((((&))))))))))).)).))))
.............
-36.5
BCL-2 2500 hsa-miR-16 ..(((((.....((((((((((&))))))))))..)))))...
............
-23.3
BCL-2 2500 hsa-miR-195 .(((((....(((((((((((&))))))))))).)))))...
............
-26.5
c-MYC 114 hsa-let-7c (((((((......(((((((((&)))))))))......)))))
))..........
-24.5
c-MYC 114 hsa-let-7b (((((((......(((((((((&)))))))))......)))))
))..........
-24.5
ERB B2 37 hsa-miR-214 ..(((((.((...(((((((.&.))))))))).)))))......
..........
-24.6
ERB B2 361 hsa-miR-132 (((((........(((((((..&..))))))).......)))))..
.........
-23.26
ERB B3 9 hsa-miR-302d .((((((.....(((((((((((&)))))))))))))))))
...............
-25.00
ERB B3 254 hsa-miR-515-3p ..(((((......((((((((&)))))))).....))))).....
.........
-22.60
ERB B3 648 hsa-miR-17-5p ..((((((((.....(((((((((&))))))))).....))))
))))..........
-26.80
ERB B3 648 hsa-miR-20b .((((((((.....(((((((((&))))))))).....)))))
)))..........
-26.80
ERB B3 648 hsa-miR-20a .((((((((.....(((((((((&))))))))).....)))))
)))..........
-25.50
ERB B3 648 hsa-miR-106a ..((((((((.....((((((((.&.)))))))).....)))))
)))..........
-25.10
FRAT 1 127 hsa-miR-125b ((((((((....(((((((((.&..))).)))))))))))))
)............
-23.8
FRAT 1 127 hsa-miR-100 (((((((.....((.((((((.&.))))))))...))))))).
............
-24.7
FRAT 1 271 hsa-let-7b (((((((.(((((((..(((((&)))))....))))))).))
)))))........
-30.8
FRAT 1 796 hsa-miR-34a .(((((((((......((((((&)))))).)))))))))....
............
-23.4
FRAT 1 1295 hsa-miR-15b ((((((((((((((...((((.&))))...)))))))))))
)))...........
-27.6
K-RAS 2004 hsa-miR-371 .((((....((((((((((..&.)))))))))).......))))
..........
-24.8
K-RAS 2294 hsa-miR-92 .((((((((......(((((((&)))))))..))))))))...
............
-23.4
K-RAS 3137 hsa-miR-147 .(((...((((((((((((.&..)))))))))))).....)))
..........
-23.5
K-RAS 4832 hsa-miR-125a .((((((.....(((((((((..&.))))))))).....)))))
)...........
-26.6
K-RAS 4946 hsa-miR-147 .((((((((..(((((((((&.))))))))).....))))))
)).........
-24.3
K-RAS 2355 hsa-let-7i ..((((....((..(((((((&)))))))..))...)))).....
.........
-18.8
K-RAS 2783 hsa-let-7f ((((...(((((.(((((((((&)))))))))..)))))...
)))).........
-18.3
K-RAS 3125 hsa-let-7b ((((((((((.....(((((((&)))))))))))))..)))
).............
-18.6
K-RAS 4919 hsa-let-7b (..(((.((((..(((((((((&)))))))))..))))))).
.)...........
-24.8
K-RAS 4919 hsa-let-7c ..(((..((((..(((((((((&)))))))))..)))).....
))).........
-21.4
K-RAS 4919 hsa-let-7i .((((((.(((.(((((((((&)))))))))..))).))).
)))..........
-19.6
Examples of predicted miRNA/oncogene interactions. Several important oncogenes and their potential miRNA regulators were arbitrary selected from the full list of 294 
genes (Additional file 1), to be shown as examples. RNAfold "dot-and-bracket" format was used to show secondary structures of miRNA/mRNA duplexes (left side of 
appropriate structure corresponds to miRNA sequence in 3'-5'orientation; right side corresponds to predicted mRNA binding site in 5'-3' orientation). Brackets represent 
paired and dots non-paired nucleotides, respectively.BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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From the unfiltered results obtained automatically by the
programme, we chose the group of records showing rela-
tively weak 3' pairing but very strong and extensive 5' pair-
ing (seed site), which is characteristic of strong and
potentially positive targets [59].
Of the interactions predicted, we thought that the poten-
tial interaction between the oncogene c-MYC and the let-
7c miRNA could be of particular interest due to the known
importance of the gene and the conservation of the spe-
cific miRNA. The secondary structure of this pair shows
good complementarity in the 5' of the let-7c miRNA (9 nt)
which is considered very important for the target recogni-
tion [56]. In addition, good pairing in the 3' region was
found in silico (Fig. 1A). The duplex structure seems to
have all the properties for an animal miRNA binding that
are needed for down-regulation of a gene. The binding of
let-7c miRNA is in position 114 of the 3'UTR. Further-
more, independently of the first analysis, we inspected in
detail miRNAs binding sites of human and murine forms
of the MYC gene. In each tested MYC mRNA we could
detect and identify in the 3' UTR a binding site for a rep-
resentative of the human/murine let-7 member of miR-
NAs (Additional file 2).
Schematic representation of the predicted interaction between miRNA and the mRNA target 3'UTR site Figure 1
Schematic representation of the predicted interaction between miRNA and the mRNA target 3'UTR site. Fig-
ures (A) and (C) show wild-type interactions for c-MYC/7c and BCL-2/16, respectively. In figures (B) and (D) the predicted 
interaction between miRNA and the respective mutated binding site is depicted (B for c-MYC, D for BCL-2 ). (E) microRNA 195 
from the miR-15 family was predicted to be a reliable regulator for BCL-2 gene (see text for more details).BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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Sethupathy et al. [60] analysed human/murine experi-
mentally validated examples and showed that there is a
tendency for the binding sites to occur closer to the start
of the UTR than to the end. We have also checked all the
human/murine MYC potential interactions with let-7 and
found that they are all located in the 2/3-th region of the
3'UTR. However, there is no obligatory region that has
been proven so far for the localization of the miRNA bind-
ing sites within the 3' UTR. miRNA sites also have prefer-
ences to the of 3'UTRs sequence composition. According
to Robins et al., the large majority (~75%) of human
miRNA target genes have AT-rich 3'UTRs [61]. We have
tested our human/murine genes, and the great majority
have high AT content (between 51% and 70%, with an
average of 61%).
Our in silico analysis revealed also an additional interac-
tion of potential interest (Fig. 1C). It has been previously
reported that miR-15a and miR-16-1 target BCL2 mRNA
[51]. We have found that also another member of the
miRNA 15 family is predicted to bind exactly on the same
site as miR-16 (pos. 2500 in the BCL2  3'UTR). This
miRNA, miR-195, shares the same seed region with miR-
15 and miR-16 and shows high similarity to the rest of the
miR-15 family sequence. The free energy of the miR-195/
BCL2 (26.5 kcal/mol) is even stronger than for miR-16/
BCL2 (23.3 kcal/mol). The secondary structure is the same
perfectly symmetrical 5'dominant site, with an even
smaller central loop (Fig. 1E). The microarray analysis
revealed that miR-195 is an immuno-specific miRNA, and
is expressed at a high level in all organs of the immune
system [62]. This miRNA is abundant in lymphocytes and
is encoded in a region of chromosome 17 which is miss-
ing in some forms of CLL [63-65].
Experimental validation
We concentrated on target genes forming almost perfect
duplexes with their miRNA partners in the 5' "seed"
region, with a central loop and having an arbitrary free
energy around -23 kcal/mol, which is a typical energy
value for formation of this sort of structures. Therefore,
two very important oncogenes BCL-2  and  c-MYC  were
chosen from the list for further investigation, and their
potential micro-regulators miR-16 and let-7c, respec-
tively.
For the experimental verification of the predicted interac-
tions between selected miRNAs and their putative targets,
experiments using sensor constructs carrying a Renilla
luciferase reporter were performed. miRNAs' activity on
reporter genes bearing the miRNA-binding sites have been
previously demonstrated [22,23,66]. Only sequences car-
rying binding sites for appropriate miRNAs were used.
Since it is known that most of the mammalian targets
often contain binding sites for multiple miRNA [23], con-
structs carrying a single binding site for the tested miRNA
and constructs carrying binding sites repeated three times
were used (Fig. 2). Moreover, constructs having mutations
disrupting the native pairing within the binding region (5'
seed site) of the candidate miRNAs (designated as MUT)
and constructs showing perfect complementarity (PM) to
them were generated as well, in order to provide a nega-
tive and a positive control, respectively. All types of cas-
settes prepared were placed into the phRL-TK-BstEII
vector, downstream of the hRluc gene at BstEII sites.
We performed the transfection of HeLa cells for sensors of
BCL-2 and c-MYC miRNA potential binding sites. Each
time, four constructs were tested in parallel: an empty
luciferase vector (Control), wt potential binding site for
appropriate miRNA (WT_b.s), mutated binding site
(MUT_b.s) and site with full complementarity (PM_b.s).
Since the miRNAs of interest have been shown to be
expressed in HeLa cells at relatively high levels [62] there
was no need for miRNA precursor over-expression. Luci-
ferase activity was measured and normalised against the β-
galactosidase expression.
Although at the time we were conducting our experiments
the regulation of BCL-2 by miR-16 was reported [51], we
nevertheless decided to include this interaction in the
study, as an additional control of the approach we used
for miRNA target verification. In our system, using only
the expected miR-16 binding site of BCL-2 3'UTR, we con-
firmed that BCL-2 oncogene is targeted by miR-16. More
Constructs used for the validation of miRNA- oncogene  interaction Figure 2
Constructs used for the validation of miRNA- onco-
gene interaction. The sequence of the BstEII cassette is 
shown on the top. Predicted binding sites for appropriate 
miRNAs were inserted into BstEII site. Single target sites or 
triplets were used for c-MYC and BCL-2 genes (for sequences 
see the Additional file 4).BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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specifically, we obtained 1.78 fold reduction of the luci-
ferase activity even when the sensor construct carried a
single binding site for miR-16. The activity was decreased
up to 56% compared to 100% in the control (Fig. 3A). The
suppression was stronger when a construct that contained
a triple miR-16 binding site was used and resulted in 2.18
fold downregulation – only 45.8% of the original luci-
ferase activity measured (Fig. 3B). The HeLa transfections
were repeated 6 and 10 times, respectively, and the score
is presented as an average.
The sensor construct carrying the c-MYC potential single
binding site for let-7c appeared to be consistently well
down-regulated by let-7 microRNA. The luciferase activity
dropped to 72% of the empty vector (about 1.41 fold
reduction). Since a single mutation at position 3 of the
"seed" in the c-MYC MUT_b.s -sensor (our negative con-
trol) – was not sufficient for full reversion of the luciferase
activity compared to WT_b.s, we decided to test also c-
MYC doubleMUT_b.s, a construct bearing two mutations
in the 5' "seed" element, one at position 3 and one at posi-
tion 5 (Fig. 1B). The transfection experiments confirmed
that the down-regulation of c-MYC oncogene is highly
reproducible. As expected, the luciferase activity for c-MYC
doubleMUT_b.s showed a more efficient de-repression,
becoming almost equal to the control experiment
(98.1%). Conversely, the activity of luciferase measured
for the c-MYC PM_b.s construct was very low (17.3%).
The data represent the average score from 10 independent
experiments (Fig. 3C).
To confirm further that cMYC oncogene is a real target for
let-7c we performed next transfections of HeLa cells, using
anti-let-7c inhibitor in order to block the predicted inter-
Relative repression of luciferase expression standardised to a transfection control Figure 3
Relative repression of luciferase expression standardised to a transfection control. The following reporter con-
structs were tested: (A) BCL-2 reporter constructs carrying a single binding site for miR-16, (B) BCL-2 reporter construct car-
rying a triple binding site for miR-16, (C) c-MYC reporter constructs carrying a single binding site for let-7, (D) c-MYC reporter 
constructs including sensors carrying the whole 3'UTRs from the c-MYC gene. The luciferase activity was normalised against β-
gal expression. Results are presented in % (100% – luciferase vector with no binding site, (+) control). Average from several 
experiments is shown (details in the text).BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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action of let-7c with our sensor constructs. The co-trans-
fection of anti let-7 resulted in derepression of the
luciferase activity in sensor constructs (the exception was
the construct bearing PM b.s for c-MYC), although dere-
pression was not equally efficient for all sensor constructs
(Additional file 3).
It is worth noting, that all perfect matching constructs
used as positive controls interacting with the miRNA
under investigation through the siRNA pathway
[10,67,68] worked consistently well. The luciferase activ-
ity in all studied cases was always repressed at a very low
level, ranging from 5% up to 30% of the empty reporter
construct.
Further we intended to investigate whether the effect of
let-7 on the c-MYC binding site-containing reporter could
be recapitulated when the whole 3'UTR of c-MYC  was
present downstream of the luciferase gene. This is impor-
tant since it is possible that structural features of the UTR
may hinder the miRNA/target interaction. For this pur-
pose, the whole c-MYC 3'UTR was cloned into the luci-
ferase vector. In addition, two point mutations in the seed
region of the potential let-7c b.s in the c-MYC 3'UTR were
introduced, similarly to the c-MYC doubleMUT_b.s sen-
sor construct carrying only the let-7c b.s (compare to Fig.
1B). Again, a series of HeLa transfections was performed.
Five constructs were tested in parallel: an empty luciferase
vector (negative control), the construct carrying the poten-
tial b.s for let-7c (WT_b.s), the construct with the whole
cMYC 3'UTR (WT_3'UTR), the construct with the mutated
c-MYC 3'UTR (MUT_3'UTR) and the construct carrying b.s
with full complementarity (PM_b.s – our positive con-
trol). Both c-MYC constructs, the one carrying the poten-
tial let-7c binding site only and the construct carrying the
whole 3'UTR of c-MYC, showed a suppression of the luci-
ferase activity compared to the control vector, although
not at equal levels to each other. The construct with the
single let-7 b.s reduced the luciferase activity to 66.8 % of
the control, while for the construct with the whole 3'UTR
the reduction was on average up to 45.6 %. In the case of
the  c-MYC  MUT_3'UTR sensor the luciferase activity
reached 51.2 % of the control, suggesting that the muta-
tion disturbing the potential b.s for let-7c restored the
activity of luciferase when compared to the WT_3'UTR
sensor, however, not efficiently compared with the con-
struct bearing the let-7 binding site only (WT_b.s). The
HeLa transfections and luciferase assays were repeated 6
times and the score is presented as an average (Fig. 3D).
Finally, we determined the extent to which endogenously-
expressed c-MYC is subjected to the regulation by let-7
microRNA. We have monitored c-MYC expression at the
mRNA and protein levels following the inhibition of let-7
with the antisense synthetic let-7 oligo (anti-let-7c from
Dharmacon) in HeLa cells. 48 h post-transfection RNAs
and proteins were extracted from HeLa cells and analysed
by Northern and Western methods, respectively. We
detected a mild increase at the mRNA level and quite a sig-
nificant increase at the protein level (Fig. 4A and 4B). In
addition to the increase of c-MYC protein level, we also
observed accelerated growth rate of the transfected HeLa
cells, eventually causing early cells' death (not shown).
On the contrary to the specific effect caused by the intro-
Inhibition of let-7c enhances cMYC mRNA and protein levels Figure 4
Inhibition of let-7c enhances cMYC mRNA and protein levels. Northern blot (A) and Western blot (B) and analyses 
were performed 48 hours after transfection of HeLa cells with anti-let-7c inhibitor. RNAs and protein samples were extracted 
from non-transfected HeLa cells and cells transfected with the anti-let-7c and anti-miR-195 oligos, as indicated in figures. In 
case of the western analysis a positive control (protein extract from lymphoma cells overexpressing cMYC) was included as 
well.BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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duction of anti-let-7c, we did not observe similar changes,
either at mRNA or protein levels, when an irrelevant anti-
miR was used (synthetic antisense miR-195 oligo).
Discussion
More than 400 human miRNAs have been identified so
far [69] and bioinformatics analyses predict that the total
number may be around 1000 [6,70]. More than 200 miR-
NAs have been already correlated with cancer [30]. More-
over, the expression profile of miRNAs from cancer tissues
has been suggested to be prognostic concerning the speed
of cancer development and its malignancy [41,71,72]. A
correlation between the expression of particular miRNAs
and their effects on target oncogenes followed by tumour-
igenesis is beginning to gain evidence. Of particular inter-
est is the possibility that the growth of cancer cells can be
repressed by artificial modulation of the level of miRNAs
[73-75]. Despite the accelerated research interest in the
miRNA-regulation, there are only a few examples where
an oncogene or a tumour suppressor has been identified
as a miRNA target and the regulatory connection validated
[40,51,53,54]. Our results indicate that the expression of
the c-MYC gene, which is one of the critical oncogenes, is
modulated by let-7, expanding the number of validated
oncomirs.
Since the significant increase of miRNA targets, all previ-
ous validations (including some "oncomirs") have been
gathered by Sethupathy at al, in a database called TarBase
[60]. The assay of luciferase as a reporter gene has been
widely used for the verification of human targets; more
than 80% of human targets in the TarBase were validated
by this method. However, this validation system has vari-
ations depending on the inserted fragment of the target
3'UTR. Either the full-length 3'UTR of mRNA [40,53,76],
or only a segment containing the binding site [23,51], or
even only the miRNA predicted binding site [22,52] has
been inserted in appropriate reporter constructs. Insertion
of multiple binding sites should ensure higher efficiency
of the sensor used, since cooperativity of multiple miRNA
binding sites has been reported [77,78]. However, the
degree of miRNA-mediated translational repression may
depend also on different factors, for example particular
miRNA and mRNA concentrations, the accessibility of the
binding site and its context [22]. Moreover, the valida-
tions mentioned above were achieved by different experi-
mental techniques and for different miRNAs, making it
difficult to compare the results.
In the present work we have used synthetically designed
miRNA-binding sites for miRNAs of interest, cloned
downstream of the luciferase reporter gene. We have
tested constructs with single and triple binding sites. We
were somewhat surprised to find that a considerable
down-regulation was achieved even when sensors carried
only one binding site, without the addition of miRNA pre-
cursors. A significant repression was observed for both c-
MYC and BCL-2 single binding sites. The miRNAs studied
here, let-7c and miR-16, are predicted to interact with
their potential binding sites c-MYC  and  BCL-2  respec-
tively, in a so-called canonical interaction, in agreement
with the report that the canonical sites have higher bind-
ing energy and may be more efficient suppressors [26].
However, the use of triplet constructs not only resulted in
the stronger regulation but also ensured more reproduci-
ble outcome. Moreover, we could show that the predicted
miRNA binding site functions in the context of the entire
3'UTR. Cloning of the whole c-MYC 3'UTR into the luci-
ferase vector resulted in a very strong reduction of the luci-
ferase activity, the strongest effect observed in our set of
experiments. Mutagenesis of two nucleotides in the let-7c
binding site (nt 3 and 5 in the seed region) could only
marginally restore the luciferase activity, although the
same mutations caused significant upregulation of luci-
ferase expression in the b.s construct (Fig 3D). This indi-
cates that other miRNA binding sites present in the c-MYC
3'UTR cooperate in the modulation of gene expression.
Indeed, other miRNA binding sites have been bioinfor-
matically identified in the c-MYC 3'UTR (not shown). We
believe that the interaction studied here, let-7c/c-MYC
(pos. 114 of the UTR) is the strongest and the most impor-
tant for the regulation of c-MYC  expression, however,
miRNAs are likely to contribute to the regulation of cMYC.
Although now there are many programmes established
for the computational prediction of miRNA targets
(reviewed in [79]), the large number of predicted targets
makes it difficult to choose the best candidates for further
experimental verification in a biological system. The
advantage of our bioinformatics approach is the possibil-
ity of relatively fast, manual scanning of the secondary
structures formed by analysed pairs of putative interactors
through the use of the RNAfold dot-and-bracket format. It
is worth noticing, that in the results list of our scanning
important oncogenes can be found (for example BCL-2
and RAS), that have already been proven as targets for par-
ticular miRNA (see Additional file 1). Such an outcome
supports the suitability of the scanning algorithm used
here.
So far, only a handful of miRNAs and their targets have
been characterized in detail. Although the BCL-2/miR-16
interaction has been already shown [51], we demonstrate
it here with the use of BCL-2 binding site for miR-16 only
and not BCL-2 3'UTR segment of 546 bp, as before [51].
Here we demonstrate that c-MYC is targeted by let-7. We
show that 22-nt sequence from the c-MYC 3'UTR, pre-
dicted to be a binding site for let-7c, is enough to cause
down-regulation of a reporter gene in HeLa cells. In addi-
tion, suppression of let-7 miRNAs in these cells by anti-BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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let-7 significantly recovers reporter gene expression. More-
over, the suppression of let-7 in HeLa affects also the
expression of the endogenous c-MYC, leading to an
increase at both mRNA and protein levels. Mammalian
miRNAs affecting target mRNA levels in addition to pro-
tein levels have been reported before [40,80] although
there are also examples of endogenous mammalian
mRNAs that are regulated by miRNAs at the level of trans-
lation without any change in target mRNA levels [51,55].
Based on our analysis it is not possible to specify which
member(s) of the let-7 family is (are) responsible for the
down-regulation of c-MYC. Let-7c, let-7b and let-7i (all
with theoretically good efficiency) may bind to the same
site in 3'UTR of c-MYC (Table 2). Biological data may give
some clues as to which of the let-7 family members may
be more likely to interact with c-MYC in vivo. In 80% of
breast cancers, c-MYC is over-expressed, indicating that its
potential miRNA regulator could be down-regulated in
these cases. However, the expression level of let-7b both
in normal and cancer breast tissues is the same [32]. More-
over, the down-regulation of let-7 family members
(including let-7c but excluding let-7b) has been reported
elsewhere for breast cancer [46]. In this last report, the
down-regulation of let-7 was shown to correlate with
metastasis or higher proliferation index, which could
additionally support our hypothesis for c-MYC involve-
ment [46]. Furthermore, the next evidence for our predic-
tion of c-MYC/let-7c interaction is the fact that frequent
deletions in chromosome 21 (21q21) have been reported
in cases of lung and colorectal carcinomas and their
metastases [81-84]. The same genomic location is shared
by the let-7c gene, while the other candidates such as let-
7b or 7i are located on chromosomes 12 and 22, respec-
tively. The deletions in a region coding let-7c would be the
simplest explanation for the reduced level of let-7c in can-
cer tissues, the miRNA diminishing the activity of c-MYC,
therefore contributing to the enhanced proliferation and
tumourigenesis.
It has been shown that the concentration of the MYC pro-
tein is critical for the conversion, persistence or regression
of the liver tumours [85]. The cause of spontaneous c-
MYC up-regulation is not yet clear. Calin at al. proposed
that chromosomal translocation could bring MYC genes
under the control of promoters for microRNAs, so that the
gene will be over-expressed [39]. An alternative trigger for
c-MYC over-expression could be reduced activity of the
regulator, such as a let-7c that negatively modulates gene
expression at translational level. Spontaneous c-MYC
over-expression could be therefore the result of down-reg-
ulation or loss of specific let-7 loci.
Although at present a comprehensive picture of the regu-
latory function of the let-7 miRNA family cannot be
drawn, it is tempting to speculate on possible roles for this
miRNA family in a complex network of interacting, pro-
proliferative/proapoptotic factors. Mounting evidence
shows that the expression of the RAS oncogene is regu-
lated by let-7, and that RAS is significantly over-expressed
in lung tumour samples [40]. The 3'UTRs of the human
RAS  genes contain multiple let-7 complementary sites,
allowing let-7 to regulate RAS [40]. In humans, let-7 is
expressed in normal adult lung tissue but poorly
expressed in case of lung cancers [40,71], which suggests
that this miRNA may function also as a tumour suppres-
sor. Moreover, it has been shown that over-expression of
let-7 inhibited cell growth of a lung cancer cell line in vitro
[71]. However, the mechanism by which let-7 regulates
cell cycle is unknown. c-MYC is another important onco-
gene with the ability to induce both cell proliferation and
apoptosis [86]. In addition, RAS  and  c-MYC  function
together – both are key components of the signaling path-
way, regulated by the mitogen activated protein kinases
(MAPK) [87,88]. It has been reported that induction of c-
MYC expression correlates with induction of miR-17 clus-
ter, consisting of six miRNAs: 17-5p, -18, -19a, -19b, -20
and -92 [31]. Moreover, c-MYC regulates the transcription
of miRNAs from miR-17 cluster and two of them (miR-
17-5p and miR-20) regulate transcription factor E2F1 at
the translational level [52], which is also transcriptionally
activated by c-MYC [89].
Conclusion
A large number of potential miRNA target sites in 54.8%
(80/149) of human oncogenes has been proposed and
presented here based on an in silico analysis. Targets for
different oncomirs, validation of which would be of spe-
cial interest, have been presented. Moreover, two pre-
dicted interactions (cMYC/let7 and BCL2/miR-16) have
been tested experimentally in a reporter gene assay, which
presently seems to be the "gold-standard" method to val-
Table 2: Possible let-7 family members that can interact with 3'UTR of c-MYC
3'UTR position miRNA name secondary structure free energy
114 hsa-let-7i .(((((...(((((((((&))))))))).....)))).))))......... -20,5
114 hsa-let-7b (((((((......(((((((((&)))))))))......)))))).......... -24,5
114 hsa-let-7c (((((((......(((((((((&)))))))))......)))))).......... -24,5
114 hsa-let-98 .(((((((((...(((((((((&)))))))))))))))))).............. -20,8BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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idate miRNA::target interactions. Both let-7 and miR-16
have been shown to downregulate their target oncogenes,
c-MYC and BCL-2, respectively. Given the known impor-
tance of the regulatory miRNA we tested (let-7) and the
targeted oncogene (c-MYC) studied, the validation of a
let-7/c-MYC interaction may be of particular interest. The
miRNAs that are encoded by let-7 family are conserved
between mammalian species, both at the sequence level
and at their temporal expression patterns, which probably
indicates their general role in gene regulation [16]. The c-
MYC transcription factor, on the other hand, is one of the
most potent and frequently deregulated oncoproteins in
human cancers [90,91], therefore its deregulation is
regarded as a hallmark of many cancers (reviewed in
[92]).
Methods
Retrieving the Homo sapiens UTRs sequences
The UTR sequences were retrieved and collected by accu-
rate parsing from EMBL/GenBank and "UTR Database"
(UTRdb, release 15.0) [93-96]. The whole human 3'UTR
dataset was provided as a multi-GenBank file. The current
GeneBank format was converted to a FASTA file using
BioPerl modules for biological database parsing.
Extraction of the oncogenes
For the gathering of all oncogenes (and also some other
cancer related sequences) a Perl script was developed, for
parsing the local dataset files and making the onco-collec-
tion of sequences. Entries were scanned and collected by
description (definition and keywords fields) from the
original GenBank entries. The local database of oncogenes
was extended by some sequences which were obtained
from EMBL nucleotide sequence database. The final set of
sequences, containing 146 entries, was structured as a
multi-FASTA format file.
miRNA binding site analysis and 2D shape filtering of RNA 
duplexes
All oncogene sequences were scanned with the core algo-
rithm of microInspector [97]. Using the program as com-
mand line script, the software was able to process whole
sets of sequences and analyse them for all possible human
miRNA binding sites. The folding temperature was set to
37°C. We used a cut-off value -18 kcal/mol. For the miR-
NAs database we selected all Homo sapiens sequences from
the "miRNA Registry" Release 7.1 [98].
The outcome results were subjected to further examina-
tion by considering the suggested properties of animal
miRNA binding sites [59] using an external Perl filter. The
minimal pairing in the seed was set as 6 nucleotides, inde-
pendently of nucleotide at position one. Following the
main central loop/bulge (which was considered optional)
the filter allowed structures having full complementarity
or only few (up to 3) unpaired nucleotides at the 3' end
(Fig. 5).
Vectors and DNA constructs
To generate reporter vectors bearing miRNA-binding sites,
a mammalian expression vector phRL-TK (Promega, Mad-
ison, US) carrying the Renilla luciferase gene (hRluc) as a
reporter was used. It was modified in such a way to protect
from re-ligation, thus simplifying the cloning of short
sequences. Double restriction sites for BstEII enzyme were
inserted downstream from the stop codon of the luci-
ferase gene. Specific oligonucleotides having BstEII ends
and containing binding sites (single or triple repeats) for
the analysed microRNAs: c-MYC b.s. for let-7c and BCL-2
b.s. for miR-16 were generated (Metabion, Martinsried,
Germany). The appropriate oligos were then annealed by
boiling and gradually cooling down, phosphorylated and
cloned into the modified phRL-TK-BstEII vector at the
BstEII sites downstream of hRluc gene (Fig. 2). For all sen-
sor constructs three types of cassettes were prepared and
studied side by side: wild type (WT), carrying mutations
(MUT) and perfect match (PM). In addition, to check
whether the potential miRNA binding sites function in
the context of the entire 3'UTR, the whole c-MYC 3'UTR
was cloned into the same luciferase vector (at Xba I – Not
I restriction sites) using the following primers: Fw-
5'ACTCTAGATGCGTAAGGAAAAGTAAGGA and Rev-
5'AAGGCCGCATGATATATTTGCCAGTTATT. Moreover,
point mutations in the potential let-7c binding site were
inserted in the same positions as for the construct carrying
let-7c b.s only (seed region, pos. 3rd and 5th; compare Fig.
1B), using QuikChange Multi Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA) and primer sequence: 5'-
TAGCCATAATGTAAACTGACCCAAATTGGACTTT-
GGGCA. All constructs were verified by sequencing. Addi-
tionally, anti-let-7c (Dharmacon, Chicago, USA) was used
to inhibit the expression of let-7c. The sequences used in
our studies are listed in the Additional files (Additional
Preferred structure for the external filter Figure 5
Preferred structure for the external filter. Outline of 
the miRNA-target structure selected by the external filter. 
The structure selected by the filter should have full comple-
mentarity in the 5'miRNA-end, optionally a central loop/
bulge and good 3' pairing with up to three mismatches.BMC Molecular Biology 2007, 8:79 http://www.biomedcentral.com/1471-2199/8/79
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file 4). Positions of mutations in the MUT constructs are
indicated in bold letters.
Transfection assay
Human HeLa 229 cell line (LGC Promochem, ATCC
Number: CCL-2.1) was grown in Dulbecco's Modified
Eagle's Medium (DMEM) with 10% fetal bovine serum
(FBS) and gentamycine (50 μg/ml) at 37°C, in a humified
atmosphere of 5% CO2. The cells were transfected in the
12-well plates in serum-free DMEM by using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, California) or
siIMPORTER, siRNA and Plasmid DNA Transfection Rea-
gent (Upstate, Charlottesville, USA), according to manu-
facturers' instructions. For each transfection experiment,
100 ng of appropriate sensor construct and 500 ng of nor-
malization vector pCMVβ (Clontech, Mountain View,
USA) expressing β-galactosidase were used in order to
obtain optimal results. β-gal vector was used as a control
for transfection efficiency. HeLa cells were also transfected
with the phRL-TK-BstEII vector lacking miRNA-binding
sites to demonstrate the standard luciferase activity. Cells
were harvested 48 h after transfection and assayed both
for luciferase activity and β-gal expression. The luciferase
activity was measured using Renilla Luciferase Assay Sys-
tem (Promega, Madison, USA) with a FB 12 Luminometer
(Berthold Detection Systems, USA). For the inhibition of
endogenous let-7c miRNA in HeLa cells the transfection
of anti-let-7c oligo (Dharmacon) at a final concentratra-
tion of 50 nM was performed, using siIMPORTER reagent
(Upstate) according to manufacturers instructions. Cells
were harvested 48 h after transfection and used for north-
ern and western analyses. Inhibition of endogenous let-7c
in order to restore luciferase activity of sensor constructs
(Additional file 3) was achieved using the concentration
of antisense let-7c oligo, as indicated in the figure. To pro-
vide an equal amount of transfected DNA the GAPAS
oligo (GTGGATATTGTTGCCATCA), reported not to target
any cellular miRNA, was used [66].
Figures for the tranfection assays were made by summariz-
ing all repeats for the particular construct. Values for error
bars were calculated using a formula for standard error of
the mean, which is the standard deviation of the sampling
distribution of the mean. The formula for the standard
error of the mean is: σM = σ/√N, where σ is the standard
deviation of the original distribution and N is the sample
size (the repetition number).
Northern and Western blot analyses
Total RNA was extracted from HeLa cells using Trizol Rea-
gent (Invitrogen). Northern blot was performed as
described before [99]. For probing, DNA fragments corre-
sponding to c-MYC 3'UTR and 18S rRNA (a loading con-
trol) were labelled by random primed incorporation of
[32-P] dATP and dCTP (RadPrime DNA Labelling System,
Invitrogen).
For the Western analysis total protein extracts from HeLa
cells were used. 48 h after transfection cells were lysed
with EBC buffer (50 mM Tris pH-8, 170 mM NaCl, 0.5 %
NP 40, 50 mM NaF) supplemented with protease inhibi-
tors. 30 μg of protein lysate was separated by 10% SDS-
PAGE and transferred to PROTRAN nitrocellulose mem-
brane (Schleicher & Schuell) in 25 mM Tris, 200 mM gly-
cine, 20% methanol, at 30 V overnight at 4°C. After
blocking nonspecific binding sites with 5 % nonfat milk
in PBS/Tween, the membrane was incubated for 2 h at RT
with primary antibody anti-cMYC (monoclonal, diluted
1:200) and then for 1 h with the secondary anti-mouse
antibody (alkaline peroxidase-conjugate, diluted
1:10000). After washing in PBS/Tween, the detection was
performed using SuperSignal WestPico Trial Kit (Pierce,
Rockford, IL, USA)
Abbreviations
miRNA: microRNA, b.s: miRNA binding site; BCL-2: B-cell
leukemia/lymphoma 2; c-MYC: v-myc myelocytomatosis
viral oncogene homolog (avian)
Note added in proof
During the review process, work by Kumar et al. (doi:
10.1038/ng2003; 2007) was published showing that glo-
bal repression of miRNA maturation promotes cellular
transformation and tumorigenesis. They correlate this
processes with the lack of let7 regulation on the RAS and
cMYC genes.
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